White House drops Heidi Overton nomination for FDA commissioner

WASHINGTON — The White House is dropping the nomination of Dr. Heidi Overton to head the Food and Drug Administration, a White House official confirmed Tuesday.

The decision comes a day before the Senate Health Committee is set to vote on whether to advance his nomination to the full Senate for confirmation.

Axios was first to report the White House decision.

The move follows weeks of doubt from top Republicans on the Health, Education, Pensions and Labor Committee. To advance to the full Senate, Overton would have needed 11 votes among the 21 committee members, meaning she couldn’t afford to lose a single Republican if all Democrats opposed her.

Sen. Bill Cassidy of Louisiana, the committee chairman, questioned whether Overton — a preventative medicine doctor who is in charge of domestic policy at the White House — had enough experience to lead the agency.

Before Overton’s confirmation hearing in September, Cassidy wrote on X that he had “strong concerns” about her nomination, saying her lack of management experience left her ill-prepared to lead the agency. In a post last week, Cassidy said he remains undecided.

Before joining the White House, Overton worked as policy director at the conservative think tank America First Policy Institute.

Sen. Susan Collins, Republican of Maine, told NBC News last week that she was undecided and had “not taken a position,” saying she needed to “get answers on various things.”

Sen. Lisa Murkowski of Alaska declined last week to say how she would vote. During the confirmation hearing, Murkowski questioned Overton about the political pressures surrounding access to mifepristone and criticized Overton for not taking a clear position on the subject.

Overton praised the Supreme Court’s decision to overturn Roe v. Wade and called for strict restrictions on medical abortion.

The FDA is set to complete its safety review of mifepristone in March, one of the most important decisions facing the agency.

Overton’s nomination already faced a narrow window. Democrats will take control of the Senate in January, when she will be up for reappointment, and her chances of being confirmed will then be slim.

The FDA has been without a permanent commissioner since Dr. Marty Makary resigned in May, in part because of the administration’s decision to authorize several fruit-flavored vaping products.

The vacancy adds to a long period of upheaval at the country’s main health agencies.

The Centers for Disease Control and Prevention went nearly a year without a permanent director after Health Secretary Robert F. Kennedy Jr. fired Susan Monarez just 29 days after taking office last year. Trump’s first choice for the role, former Congressman Dave Weldon, was unable to gain enough Republican support, and the agency went through a series of acting leaders before the Senate confirmed Dr. Erica Schwartz in August.

Gn headline

Logo